FDA extends review for Pfizer arthritis drug by three months

(Reuters) - The U.S. Food and Drug Administration extended by three months its review of Pfizer Inc's experimental rheumatoid arthritis treatment tofacitinib, one of the most promising new drugs in the company's pipeline.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/szizuL-rK5o/us-pfizer-fda-idUSBRE87K0JG20120821

phlebotomy courses in nj phlebotomy training in illinois phlebotomy training in brooklyn